Last reviewed · How we verify

Lidocaine lubricant

Simon Fraser University · FDA-approved active Small molecule

Lidocaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses.

Lidocaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and conduction of nerve impulses. Used for Topical anesthesia and lubrication for medical procedures, Catheterization and urological procedures, Endoscopic procedures.

At a glance

Generic nameLidocaine lubricant
Also known asxylocaine jelly (2%) AstraZeneca
SponsorSimon Fraser University
Drug classLocal anesthetic
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia / Pain Management
PhaseFDA-approved

Mechanism of action

Lidocaine reversibly binds to voltage-gated sodium channels on the inner surface of nerve cell membranes, inhibiting sodium influx and preventing depolarization. This suppresses the generation and propagation of action potentials in sensory nerves, producing local anesthesia. When formulated as a lubricant, it provides topical anesthetic effect to reduce discomfort during medical procedures or catheterization.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: